Link to Article
NYTimes.com
|
|
||||
|
This Month
Month Archive
|
Sunday, March 2
by
Lyle
on Sun 02 Mar 2008 11:48 AM EST
by
Lyle
on Sun 02 Mar 2008 11:47 AM EST
by
Lyle
on Sun 02 Mar 2008 11:45 AM EST
Link to All Articles
Feb 28 2008, 11:43 AM EST Alticor Backs Interleukin Genetics' Risk Assessment Research Company will provide $1.2 million for studies that include evaluation of osteoporosis and cardiovascular disease in Asian populations.Full Story Feb 27 2008, 12:13 PM EST Scientists Demonstrate Effects of IL-8 Gene Silencing by Liposome-Encapsulated siRNA in Ovarian Cancer Study published in Journal of the National Cancer Institute also showed that this method can resensitize tumors to taxanes.Full Story Feb 27 2008, 12:07 PM EST Genentech Adds Targets to Protein Pharmaceutical Production Deal with Sangamo Sangamo will design and engineer ZFNs that target genes supplied by Genentech.Full Story Feb 27 2008, 12:08 PM EST Sigma-Aldrich and MorphoSys Ally to Supply Research Recombinant Antibodies MorphoSys' HuCAL GOLDĀ® technology will be used to generate antibodies against novel targets provided by Sigma-Aldrich, which will tackle final distribution.Full Story Feb 26 2008, 12:13 PM EST Galderma Offers $420M to Acquire CollaGenex to Pad Dermatology Focus CollaGenex' oral therapy for rosacea will complement Galderma's topical treatments.Full Story Feb 26 2008, 12:06 PM EST Althea Technologies Spins Out Diagnostics Business New firm will focus on genetic testing services and diagnostic products related to oncology applications.Full Story Feb 25 2008, 12:54 PM EST Peptide Identified that Specifically Binds to Tumors Responding to Therapy Protein fragment linked to a light-emitting molecule was able to pick out tumors in mice two days after treatment, according to Nature Medicine paper.Full Story Feb 25 2008, 12:56 PM EST Cypress to Pay $37.5M in Cash Upfront for Proprius Pharmaceuticals Acquired line of diagnostic and prognostic tools will help the firm advance its therapy for fibromyalgia, which is under FDA review.Full Story Feb 22 2008, 11:52 AM EST Warnex Gains Rights from Xenomics to Develop AML Assay Nonexclusive license agreement covers testing of the NPMI gene mutation linked to the disease.Full Story GenEngNews.com
by
Lyle
on Sun 02 Mar 2008 11:43 AM EST
|
Search
Links
|
||